Market news

Glucotrack has completed its business combination with Lōkahi Therapeutics, transforming the company into a Lōkahi-controlled public platform focused on acquiring and advancing healthcare assets while retaining its continuous blood glucose monitoring business as a standalone subsidiary. Key Investor TakeawaysGlucotrack (NASDAQ:GCTK) completed its strategic business combination with Lōkahi Therapeutics.

By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.